Gilead Sciences, Inc. $GILD Shares Purchased by Smartleaf Asset Management LLC

Smartleaf Asset Management LLC grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 56.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,663 shares of the biopharmaceutical company’s stock after buying an additional 4,937 shares during the quarter. Smartleaf Asset Management LLC’s holdings in Gilead Sciences were worth $1,539,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. GoalVest Advisory LLC increased its position in Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares in the last quarter. Corundum Trust Company INC acquired a new stake in shares of Gilead Sciences during the 3rd quarter worth about $26,000. Harbor Asset Planning Inc. acquired a new stake in shares of Gilead Sciences during the 2nd quarter worth about $27,000. Putney Financial Group LLC grew its holdings in shares of Gilead Sciences by 53.4% during the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 94 shares in the last quarter. Finally, Howard Hughes Medical Institute acquired a new position in shares of Gilead Sciences in the second quarter valued at approximately $30,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Trading Down 0.5%

GILD opened at $151.68 on Tuesday. The stock has a market capitalization of $188.19 billion, a PE ratio of 23.52, a P/E/G ratio of 0.80 and a beta of 0.36. The firm’s fifty day moving average price is $127.92 and its 200 day moving average price is $121.31. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. Gilead Sciences, Inc. has a 12-month low of $93.37 and a 12-month high of $153.13.

Insiders Place Their Bets

In related news, Director Kelly A. Kramer sold 2,805 shares of Gilead Sciences stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $127.10, for a total value of $356,515.50. Following the completion of the transaction, the director directly owned 1,339 shares in the company, valued at approximately $170,186.90. This trade represents a 67.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $124.31, for a total value of $372,930.00. Following the sale, the chief financial officer owned 150,503 shares in the company, valued at $18,709,027.93. The trade was a 1.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 373,037 shares of company stock worth $50,731,512. Company insiders own 0.27% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on GILD shares. HSBC raised their price objective on Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a report on Wednesday, December 10th. Leerink Partners lifted their price target on Gilead Sciences from $114.00 to $146.00 and gave the company an “outperform” rating in a report on Friday, January 30th. UBS Group boosted their price objective on shares of Gilead Sciences from $145.00 to $155.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Needham & Company LLC boosted their target price on Gilead Sciences from $133.00 to $140.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Finally, Truist Financial upped their price target on shares of Gilead Sciences from $140.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday, January 27th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $136.73.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.